Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Kiadis Pharma    KDS   NL0011323407

KIADIS PHARMA

(KDS)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
04/12/2019 04/15/2019 04/16/2019 04/17/2019 04/18/2019 Date
9.84(c) 9.85(c) 9.98(c) 10.32(c) 10.46 Last
149 159 83 871 155 452 817 458 189 047 Volume
-0.81% +0.10% +1.32% +3.41% +1.36% Change
More quotes
Financials (EUR)
Sales 2018 -
EBIT 2018 -22,2 M
Net income 2018 -23,3 M
Finance 2018 19,3 M
Yield 2018 -
Sales 2019 2,25 M
EBIT 2019 -23,4 M
Net income 2019 -22,2 M
Finance 2019 9,00 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 108x
Capitalization 251 M
More Financials
Company
Kiadis Pharma is developing potentially life saving therapies for patients with late-stage blood cancers, who are in need of a transplant, an area of significant need. Kiadis Pharma is building a fully integrated biopharmaceutical company to maximize the potential of ATIR, the company's proprietary... 
More about the company
Surperformance© ratings of Kiadis Pharma
Trading Rating : Investor Rating : -
More Ratings
Latest news on KIADIS PHARMA
04/17KIADIS PHARMA : Notice of Extraordinary General Meeting of Shareholders
GL
04/17KIADIS PHARMA : to Acquire CytoSen Therapeutics, Inc.
GL
04/09KIADIS PHARMA : to present at upcoming investor conferences in April 2019
GL
03/29KIADIS PHARMA : Announces Results of Extraordinary General Meeting of Shareholde..
GL
03/05KIADIS PHARMA : Strengthens Management Team
GL
03/01KIADIS PHARMA : to present at upcoming investor conferences in March 2019
AQ
02/15KIADIS PHARMA : Notice of Extraordinary General Meeting of Shareholders
GL
02/12KIADIS PHARMA : to participate in a panel at Innovation for Health 2019
AQ
02/11KIADIS PHARMA : to participate in a panel at Innovation for Health 2019
GL
02/05Kiadis Pharma appoints Dr. Robert Friesen as Chief Scientific Officer
AQ
More news
Analyst Recommendations on KIADIS PHARMA
More recommendations
Sector news : Biotechnology & Medical Research - NEC
04/16GILEAD SCIENCES : Insitro to Collaborate on Nonalcoholic Steatohepatitis
DJ
04/15PATRICK THOMAS : Novartis Files Application for Macular Degeneration Treatment
DJ
04/12GILEAD SCIENCES : Novo Nordisk Plan NASH Collaboration
DJ
04/08GSK wins U.S. nod for two-drug HIV combination
RE
04/08Sanofi, Alnylam Complete Research Phase of Rare Disease Alliance
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart KIADIS PHARMA
Duration : Period :
Kiadis Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KIADIS PHARMA
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 20,1 €
Spread / Average Target 95%
EPS Revisions
Managers
NameTitle
Arthur K. Lahr Chief Executive Officer
Mark A. Wegter Chairman-Supervisory Board
Jan Feijen Chief Operations Officer
Scott A. Holmes Chief Financial Officer
Andrew S. Sandler Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
KIADIS PHARMA35.26%284
IQVIA HOLDINGS INC13.89%26 146
CELLTRION, INC.--.--%23 477
LONZA GROUP14.29%21 459
INCYTE CORPORATION21.06%15 924
EXACT SCIENCES CORPORATION45.50%11 546